{"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "fullTimeEmployees": 39000, "companyOfficers": [{"maxAge": 1, "name": "Mr. David A. Ricks", "age": 54, "title": "Chairman, CEO & Pres", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 4416885, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anat  Ashkenazi", "age": 49, "title": "Exec. VP & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 2125270, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.", "age": 48, "title": "Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 2716346, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anat  Hakim J.D.", "age": 53, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 1979674, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrik  Jonsson", "age": 55, "title": "EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 1673270, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald A. Zakrowski", "title": "Chief Accounting Officer & VP of Fin.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Diogo  Rau", "title": "EVP & Chief Information and Digital Officer", "fiscalYear": 2021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alonzo  Weems", "age": 51, "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leigh Ann Pusey", "age": 59, "title": "Exec. VP of Corp. Affairs & Communications", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Dozier", "age": 55, "title": "Exec. VP of HR & Diversity", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 1, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 428.38, "open": 426.06, "dayLow": 426.25, "dayHigh": 438.38, "regularMarketPreviousClose": 428.38, "regularMarketOpen": 426.06, "regularMarketDayLow": 426.25, "regularMarketDayHigh": 438.38, "dividendRate": 4.52, "dividendYield": 0.0106, "exDividendDate": 1683849600, "payoutRatio": 0.6471, "fiveYearAvgDividendYield": 1.68, "beta": 0.366995, "trailingPE": 69.19365, "forwardPE": 35.6435, "volume": 2195110, "regularMarketVolume": 2195110, "averageVolume": 3303773, "averageVolume10days": 4350080, "averageDailyVolume10Day": 4350080, "bid": 435.52, "ask": 436.8, "bidSize": 1000, "askSize": 1300, "marketCap": 413807116288, "fiftyTwoWeekLow": 283.0, "fiftyTwoWeekHigh": 438.38, "priceToSalesTrailing12Months": 14.943525, "fiftyDayAverage": 357.5424, "twoHundredDayAverage": 343.3535, "trailingAnnualDividendRate": 4.07, "trailingAnnualDividendYield": 0.0095009105, "currency": "USD", "enterpriseValue": 422014451712, "profitMargins": 0.20536, "floatShares": 947402865, "sharesOutstanding": 949273024, "sharesShort": 6198527, "sharesShortPriorMonth": 7229324, "sharesShortPreviousMonthDate": 1680220800, "dateShortInterest": 1682640000, "sharesPercentSharesOut": 0.0064999997, "heldPercentInsiders": 0.0015199999, "heldPercentInstitutions": 0.84003997, "shortRatio": 2.15, "shortPercentOfFloat": 0.0078, "bookValue": 12.444, "priceToBook": 35.030537, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1680220800, "earningsQuarterlyGrowth": -0.293, "netIncomeToCommon": 5686799872, "trailingEps": 6.3, "forwardEps": 12.23, "pegRatio": 2.07, "lastSplitFactor": "2:1", "lastSplitDate": 876960000, "enterpriseToRevenue": 15.24, "enterpriseToEbitda": 46.102, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "LLY", "underlyingSymbol": "LLY", "shortName": "Eli Lilly and Company", "longName": "Eli Lilly and Company", "firstTradeDateEpochUtc": 76253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 435.92, "targetHighPrice": 505.0, "targetLowPrice": 270.0, "targetMeanPrice": 415.04, "targetMedianPrice": 430.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 23, "totalCash": 3724900096, "totalCashPerShare": 3.924, "ebitda": 9153999872, "totalDebt": 18985299968, "quickRatio": 0.789, "currentRatio": 1.3, "totalRevenue": 27691399168, "debtToEquity": 168.087, "revenuePerShare": 30.732, "returnOnAssets": 0.09623, "returnOnEquity": 0.54794, "grossProfits": 21911600000, "freeCashflow": 5214524928, "operatingCashflow": 6291999744, "earningsGrowth": -0.29, "revenueGrowth": -0.109, "grossMargins": 0.77667, "ebitdaMargins": 0.33056998, "operatingMargins": 0.27824, "financialCurrency": "USD", "trailingPegRatio": 1.8737}